Cargando…
COVID-19: Insights into Potential Vaccines
People around the world ushered in the new year 2021 with a fear of COVID-19, as family members have lost their loved ones to the disease. Millions of people have been infected, and the livelihood of many has been jeopardized due to the pandemic. Pharmaceutical companies are racing against time to d...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8001762/ https://www.ncbi.nlm.nih.gov/pubmed/33804162 http://dx.doi.org/10.3390/microorganisms9030605 |
_version_ | 1783671305974841344 |
---|---|
author | Loo, Ke-Yan Letchumanan, Vengadesh Ser, Hooi-Leng Teoh, Siew Li Law, Jodi Woan-Fei Tan, Loh Teng-Hern Ab Mutalib, Nurul-Syakima Chan, Kok-Gan Lee, Learn-Han |
author_facet | Loo, Ke-Yan Letchumanan, Vengadesh Ser, Hooi-Leng Teoh, Siew Li Law, Jodi Woan-Fei Tan, Loh Teng-Hern Ab Mutalib, Nurul-Syakima Chan, Kok-Gan Lee, Learn-Han |
author_sort | Loo, Ke-Yan |
collection | PubMed |
description | People around the world ushered in the new year 2021 with a fear of COVID-19, as family members have lost their loved ones to the disease. Millions of people have been infected, and the livelihood of many has been jeopardized due to the pandemic. Pharmaceutical companies are racing against time to develop an effective vaccine to protect against COVID-19. Researchers have developed various types of candidate vaccines with the release of the genetic sequence of the SARS-CoV-2 virus in January. These include inactivated viral vaccines, protein subunit vaccines, mRNA vaccines, and recombinant viral vector vaccines. To date, several vaccines have been authorized for emergency use and they have been administered in countries across the globe. Meanwhile, there are also vaccine candidates in Phase III clinical trials awaiting results and approval from authorities. These candidates have shown positive results in the previous stages of the trials, whereby they could induce an immune response with minimal side effects in the participants. This review aims to discuss the different vaccine platforms and the clinical trials of the candidate vaccines. |
format | Online Article Text |
id | pubmed-8001762 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-80017622021-03-28 COVID-19: Insights into Potential Vaccines Loo, Ke-Yan Letchumanan, Vengadesh Ser, Hooi-Leng Teoh, Siew Li Law, Jodi Woan-Fei Tan, Loh Teng-Hern Ab Mutalib, Nurul-Syakima Chan, Kok-Gan Lee, Learn-Han Microorganisms Review People around the world ushered in the new year 2021 with a fear of COVID-19, as family members have lost their loved ones to the disease. Millions of people have been infected, and the livelihood of many has been jeopardized due to the pandemic. Pharmaceutical companies are racing against time to develop an effective vaccine to protect against COVID-19. Researchers have developed various types of candidate vaccines with the release of the genetic sequence of the SARS-CoV-2 virus in January. These include inactivated viral vaccines, protein subunit vaccines, mRNA vaccines, and recombinant viral vector vaccines. To date, several vaccines have been authorized for emergency use and they have been administered in countries across the globe. Meanwhile, there are also vaccine candidates in Phase III clinical trials awaiting results and approval from authorities. These candidates have shown positive results in the previous stages of the trials, whereby they could induce an immune response with minimal side effects in the participants. This review aims to discuss the different vaccine platforms and the clinical trials of the candidate vaccines. MDPI 2021-03-15 /pmc/articles/PMC8001762/ /pubmed/33804162 http://dx.doi.org/10.3390/microorganisms9030605 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ). |
spellingShingle | Review Loo, Ke-Yan Letchumanan, Vengadesh Ser, Hooi-Leng Teoh, Siew Li Law, Jodi Woan-Fei Tan, Loh Teng-Hern Ab Mutalib, Nurul-Syakima Chan, Kok-Gan Lee, Learn-Han COVID-19: Insights into Potential Vaccines |
title | COVID-19: Insights into Potential Vaccines |
title_full | COVID-19: Insights into Potential Vaccines |
title_fullStr | COVID-19: Insights into Potential Vaccines |
title_full_unstemmed | COVID-19: Insights into Potential Vaccines |
title_short | COVID-19: Insights into Potential Vaccines |
title_sort | covid-19: insights into potential vaccines |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8001762/ https://www.ncbi.nlm.nih.gov/pubmed/33804162 http://dx.doi.org/10.3390/microorganisms9030605 |
work_keys_str_mv | AT lookeyan covid19insightsintopotentialvaccines AT letchumananvengadesh covid19insightsintopotentialvaccines AT serhooileng covid19insightsintopotentialvaccines AT teohsiewli covid19insightsintopotentialvaccines AT lawjodiwoanfei covid19insightsintopotentialvaccines AT tanlohtenghern covid19insightsintopotentialvaccines AT abmutalibnurulsyakima covid19insightsintopotentialvaccines AT chankokgan covid19insightsintopotentialvaccines AT leelearnhan covid19insightsintopotentialvaccines |